Phathom Pharmaceuticals (PHAT) Assets (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Assets data on file, last reported at $305.1 million in Q1 2026.

• On a quarterly basis, Assets rose 3.71% year-over-year to $305.1 million in Q1 2026; TTM through Mar 2026 was $305.1 million, a 3.71% increase from a year earlier, with the FY2025 full-year figure at $259.1 million, down 31.5% from the prior year.
• Assets for Q1 2026 stood at $305.1 million, up from $259.1 million in the prior quarter.
• Over the last five years, Assets for PHAT reached as high as $413.8 million in Q4 2023 and fell as low as $144.0 million in Q1 2023.
• Historically, Assets has averaged $269.4 million across 5 years, with a median of $259.1 million in 2025.
• Across the five-year window, Assets sank 39.5% in 2022 and surged 151.1% in 2023, its largest moves.
• Year by year, Assets stood at $164.8 million in 2022, then jumped by 151.1% to $413.8 million in 2023, then retreated by 8.58% to $378.3 million in 2024, then sank by 31.5% to $259.1 million in 2025, then increased by 17.74% to $305.1 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $305.1 million in Q1 2026, $259.1 million in Q4 2025, and $240.3 million in Q3 2025.